Haichang Biotech key facts
as of Oct 2026- Developer of nucleic acid therapeutics designed to advance biomedical science and improve human health outcomes.
- Haichang Biotech is valued at approximately $383.7M as of Oct 2026 (last reported valuation).
- It has raised $210.7M; the latest was PE Growth/Expansion in Jul 2025.
- Notable investors include Fortune Capital, Huatai Zijin Investment, Heda Ventures, Gang Wang, Dongguan Songshan Lake Science City Venture Capital — 19 tracked in total.
- Status: Privately Held (backing).
Haichang Biotech's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch Haichang Biotech: the Monday email on marks, rounds and moves
Haichang Biotech funding rounds
No funding rounds for Haichang Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Haichang Biotech
19+Membership and data by Private Market View
Haichang Biotech valuation
Haichang Biotech's last reported valuation was $384 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
Haichang Biotech investors
19 investors are on record for Haichang Biotech, including Fortune Capital, Huatai Zijin Investment, Heda Ventures and Gang Wang.
About Haichang Biotech
Developer of nucleic acid therapeutics designed to advance biomedical science and improve human health outcomes. The company offers gene delivery platforms, targeted antitumor modalities, liposomal nanoformulations, and controlled-release drug technologies, enabling pharmaceutical manufacturers, biotechnology enterprises, and biomedical research organizations to enhance therapeutic precision, improve delivery efficiency, and strengthen clinical effectiveness.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2013
- Employees
- 115
- Website
- zjhcbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.